Hamilton Public Health offers tips for staying healthy this cold and flu season - FlamboroughToday.com

Woman that are members of the WOGE women group cooperative gathers regularly to discuss sexual reproductive health, and family planning options. Here they are going through a condom demonstration session. This paper was originally published by The Lancet on 1 October 2026. Staying the course, shaping the future: WHO's commitment to sexual health and reproductive rights – The Lancet Obstetrics, Gynaecology, & Women’s HealthAdvances in sexual and reproductive health and rights (SRHR) have been among the great public health successes of the past half-century. In particular, the past decade has delivered some of its most decisive gains. Success has never rested on a single metric. It is measured in the millions of women who have gained increased control over their health, education, and economic futures through application of SRHR. Contraception remains among the most cost-effective and life-saving interventions in health. An analysis across 172 countries estimated that contraceptive use prevents 272 000 maternal deaths in a single year, reducing maternal mortality by 44%. Access to safe abortion has followed a similar trajectory.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.